Stock Traders Purchase High Volume of Pacira BioSciences Call Options (NASDAQ:PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) was the target of some unusual options trading activity on Wednesday. Investors bought 1,981 call options on the company. This is an increase of 416% compared to the typical volume of 384 call options.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, SVP Lauren Riker sold 3,970 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $28.72, for a total transaction of $114,018.40. Following the completion of the sale, the senior vice president now directly owns 38,075 shares of the company’s stock, valued at $1,093,514. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Pacira BioSciences news, insider Jonathan Slonin sold 5,012 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $28.57, for a total transaction of $143,192.84. Following the completion of the sale, the insider now directly owns 44,569 shares of the company’s stock, valued at $1,273,336.33. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Lauren Riker sold 3,970 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $28.72, for a total transaction of $114,018.40. Following the sale, the senior vice president now directly owns 38,075 shares of the company’s stock, valued at $1,093,514. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,314 shares of company stock valued at $522,053. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pacira BioSciences

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Pacira BioSciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock valued at $149,413,000 after purchasing an additional 14,960 shares during the last quarter. Frontier Capital Management Co. LLC lifted its position in Pacira BioSciences by 15.8% during the fourth quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company’s stock valued at $70,332,000 after purchasing an additional 285,045 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Pacira BioSciences by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company’s stock worth $47,633,000 after acquiring an additional 17,949 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Pacira BioSciences in the 4th quarter worth about $40,488,000. Finally, Clearbridge Investments LLC lifted its holdings in shares of Pacira BioSciences by 2.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company’s stock worth $34,250,000 after acquiring an additional 26,463 shares during the last quarter. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

PCRX traded down $1.15 during trading on Wednesday, hitting $21.59. 676,110 shares of the company traded hands, compared to its average volume of 702,461. The company has a market cap of $1.01 billion, a PE ratio of 15.90 and a beta of 0.88. The stock’s 50-day simple moving average is $28.69 and its two-hundred day simple moving average is $29.78. Pacira BioSciences has a 1 year low of $20.52 and a 1 year high of $40.16. The company has a current ratio of 5.81, a quick ratio of 4.78 and a debt-to-equity ratio of 0.57.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.04). The company had revenue of $167.12 million for the quarter, compared to analysts’ expectations of $165.43 million. Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. As a group, sell-side analysts anticipate that Pacira BioSciences will post 2.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price objective on shares of Pacira BioSciences in a research note on Tuesday. JPMorgan Chase & Co. assumed coverage on shares of Pacira BioSciences in a research note on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price objective for the company. Finally, Barclays cut shares of Pacira BioSciences from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $38.00 to $25.00 in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.10.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.